Skip to main content

Advertisement

Log in

Survival Benefit of Induction Chemotherapy with Paclitaxel and Carboplatin Followed by Chemoradiation Versus Postoperative Treatment in Locally Advanced Gastric Cancer: A Retrospective Cohort Study

  • Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Gastric cancer remains a prevalent worldwide illness that lacks a definitive cure. Recently, induction chemotherapy followed by concurrent chemoradiation has shown promising results in achieving a significant pathological response in locally advanced gastric cancer and improving survival rates. However, the optimal regimen for this approach continues to be a subject of discussion.

Methods

This retrospective cohort study was conducted on treatment-naïve patients with locally advanced gastric cancer who were referred to Imam Hossain General Hospital in Tehran, Iran, between April 2016 and March 2019. Eligible patients met the criteria of clinical T3-4 or nodal-positive stage, or both, and had non-metastatic resectable tumors. The patients were categorized into two groups: (a) the neoadjuvant group, which received induction chemotherapy (carboplatin AUC 2 and paclitaxel 50 mg/m2 weekly for 12 cycles) followed by concurrent neoadjuvant chemoradiation (radiotherapy 45–50 Gy/1.8 Gy per fraction concurrent with capecitabine 500 mg/m2 BID and oxaliplatin 40 mg/m2 weekly), and (b) the adjuvant group, which was treated with standard chemoradiation or chemotherapy regimens. The two groups were compared regarding the 3-year recurrence rate and 3-year overall survival.

Results

A total of 102 patients were included in the study (63.7% male, mean age ± standard deviation 56 ± 13 years). Among these, 45 patients received neoadjuvant treatment, and 57 received adjuvant treatment. The neoadjuvant group had a higher proportion of patients with advanced disease (stage III: 91.1% vs. 57.9%, P = 0.001). In the neoadjuvant group, 20 patients (44.4%) achieved a complete pathologic response, and all underwent curative surgery. The neoadjuvant group exhibited a lower 3-year recurrence rate (13 [28.9%] vs. 33 [57.9%], P = 0.003) and a higher 3-year overall survival rate (36 [80%] vs. 32 [56.1%], P = 0.003).

Conclusions

Patients receiving induction chemotherapy with paclitaxel and carboplatin followed by chemoradiation demonstrated enhanced disease control and survival compared to standard adjuvant regimens. In addition, patients treated with the applied preoperative regimen in this study showed higher pathologic response and overall survival rates than in previous studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Data Availability

Raw data are available upon official request from the corresponding author.

References

  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

    Article  CAS  PubMed  Google Scholar 

  2. Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57. https://doi.org/10.1186/s13045-023-01451-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hu Q, Wang J, Xu W-G, Shao P, Li G. Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy. Precision Med Sci. 2021;10(2):78–82. https://doi.org/10.1002/prm2.12038.

    Article  CAS  Google Scholar 

  4. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus Surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. https://doi.org/10.1056/NEJMoa055531.

    Article  CAS  PubMed  Google Scholar 

  5. Lee J, Lim DH, Kim S, et al. Phase III trial comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin with Concurrent Capecitabine Radiotherapy in completely resected gastric Cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73. https://doi.org/10.1200/jco.2011.39.1953.

    Article  CAS  PubMed  Google Scholar 

  6. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33. https://doi.org/10.1200/jco.2011.36.7136.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after Surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616–28. https://doi.org/10.1016/s1470-2045(18)30132-3.

    Article  CAS  PubMed  Google Scholar 

  8. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57. https://doi.org/10.1016/s0140-6736(18)32557-1.

    Article  PubMed  Google Scholar 

  9. Slagter AE, Jansen EPM, van Laarhoven HWM, et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by Surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by Surgery versus neo-adjuvant chemoradiotherapy followed by Surgery in resectable gastric cancer. BMC Cancer. 2018;18(1):877. https://doi.org/10.1186/s12885-018-4770-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Leong T, Smithers BM, Haustermans K et al. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol 2017;24(8):2252-2258. https://doi.org/10.1245/s10434-017-5830-6.

  11. Yeh JH, Yeh YS, Tsai HL et al. Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at? Cancers (Basel) 2022;14(12). https://doi.org/10.3390/cancers14123026.

  12. Haddad RI, Posner M, Hitt R et al. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol 2018;29(5):1130-1140. https://doi.org/10.1093/annonc/mdy102.

  13. Guilbault C, Garant A, Faria S et al. Long-term Outcomes of Induction Carboplatin and Gemcitabine Followed by Concurrent Radiotherapy With Low-dose Paclitaxel and Gemcitabine for Stage III Non-small-cell Lung Cancer. Clin Lung Cancer 2017;18(5):565-571. https://doi.org/10.1016/j.cllc.2017.02.003.

  14. Takada R, Ikezawa K, Daiku K et al. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer. Cancers (Basel) 2021;13(18). https://doi.org/10.3390/cancers13184733.

  15. Sahu K, Langeh U, Singh C, Singh A. Crosstalk between anticancer Drugs and mitochondrial functions. Curr Res Pharmacol Drug Discovery. 2021;2:100047. https://doi.org/10.1016/j.crphar.2021.100047.

    Article  Google Scholar 

  16. Taghizadeh-Hesary F, Houshyari M, Farhadi M. Mitochondrial metabolism: a predictive biomarker of radiotherapy efficacy and toxicity. J Cancer Res Clin Oncol 2023;149(9):6719-6741. https://doi.org/10.1007/s00432-023-04592-7.

  17. Behnam B, Taghizadeh-Hesary F, Mitochondrial Metabolism. A New Dimension of Personalized Oncology. Cancers (Basel) 2023;15(16). https://doi.org/10.3390/cancers15164058.

  18. Ajani JA, Winter K, Okawara GS et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006;24(24):3953-3958. https://doi.org/10.1200/jco.2006.06.4840.

  19. Mizrak Kaya D, Nogueras González GM, Harada K et al. Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. Oncology 2020;98(8):542-548. https://doi.org/10.1159/000506519.

  20. Amin MB, Greene FL, Edge SB et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67(2):93-99. https://doi.org/10.3322/caac.21388.

  21. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.

    Article  CAS  PubMed  Google Scholar 

  22. Ajani JA, Mansfield PF, Janjan N et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004;22(14):2774-2780. https://doi.org/10.1200/jco.2004.01.015.

  23. Li N, Xiang X, Zhao D et al. Preoperative versus postoperative chemo-radiotherapy for locally advanced gastric cancer: a multicenter propensity score-matched analysis. BMC Cancer 2022;22(1):212. https://doi.org/10.1186/s12885-022-09297-7.

Download references

Acknowledgements

The authors are thankful to our parent institutions for supporting this work.

Funding

No funding was obtained in the preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Contributions

Conceptualized PA and AYJ; Data curation SGP and ZA; Resources SGP and ZA; Writing original draft SGP, SA, FTH; Final editing and validation FTH. All the authors have read and approved the final version of the manuscript.

Corresponding author

Correspondence to Farzad Taghizadeh-Hesary.

Ethics declarations

Ethics Approval and Consent to Participate

The study protocol is approved by the Ethical Committee of Shahid Beheshti University of Medical Sciences. (Ethical code: IR.SBMU.MSP.REC.1399.800).

Consent for Publication

NA.

Competing Interests

The authors declare no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Azadeh, P., Gholizadeh pasha, S., Yaghobi Joybari, A. et al. Survival Benefit of Induction Chemotherapy with Paclitaxel and Carboplatin Followed by Chemoradiation Versus Postoperative Treatment in Locally Advanced Gastric Cancer: A Retrospective Cohort Study. J Gastrointest Canc 55, 457–466 (2024). https://doi.org/10.1007/s12029-023-00991-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-023-00991-8

Keywords

Navigation